Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.95 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.95 |
| ▸ | KIT | P10721 | 11/20 | 0.95 |
| ▸ | LDLR | P01130 | 8/20 | 0.95 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.95 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.95 |
| ▸ | LCK | P06239 | 4/20 | 0.95 |
| ▸ | LYN | P07948 | 4/20 | 0.95 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.95 |
| ▸ | FLT3 | P36888 | 4/20 | 0.95 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.95 |
| ▸ | SRC | P12931 | 2/20 | 0.95 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.95 |
| ▸ | CA12 | O43570 | 1/20 | 0.95 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.95 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.95 |
| ▸ | STK10 | O94804 | 1/20 | 0.95 |
| ▸ | CA1 | P00915 | 1/20 | 0.95 |
| ▸ | CA2 | P00918 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL2099740 | 0.99 | ABL1 (0.95) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29366964 | 0.97 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL7901 | 0.97 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29580067 | 0.97 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1984397 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL9990634 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 0.97 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635015-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| EP-4221690-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-08-09 | — | — | EP | claimed |
| EP-2535337-B1 | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form | NOVARTIS AG (CH) | 2017-08-23 | — | — | EP | claimed |
| EP-2535337-A1 | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form | Novartis AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-12-28 | — | — | US | disclosed |
| CN-116635015-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4221690-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3189045-B1 | NOVEL SALTS OF NILOTINIB AND POLYMORPHS THEREOF | SUN PHARMACEUTICAL IND LTD (IN) | 2022-02-09 | — | — | EP | disclosed |
| US-10280153-B2 | Process for the preparation of pure nilotinib and its salt | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-05-07 | — | — | US | disclosed |
| EP-3461818-A1 | POLYMORPHIC FORMS OF NILOTINIB HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2019-04-03 | — | — | EP | disclosed |
| US-10138221-B2 | Salts of nilotinib and polymorphs thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-11-27 | — | — | US | disclosed |
| CN-108864051-A | The method for being used to prepare pure nilotinib and its salt | 意大利合成制造有限公司 | 2018-11-23 | — | — | CN | disclosed |
| WO-2010009402-A9 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010054056-A2 | NILOTINIB HCI CRYSTALLINE FORMS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010009402-A2 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016590-A1 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-01-21 | — | — | US | disclosed |
| US-20080269269-A1 | Protein kinase inhibitor; purity; polymorphism | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| CN-101228150-A | Crystalline forms of 4-methyl-N- [ 3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl ] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1912973-A2 | CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | Novartis AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015870-A2 | CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | NOVARTIS AG (CH) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269269-A1 | Protein kinase inhibitor; purity; polymorphism | MAP4K2, MAP4K1, CSNK1A1 | ABL1 75/4885BCR 1101/4885KIT 813/4885 |
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, ABCG2, LIPA | ABL1 1/4885BCR 89/4885KIT 247/4885 |
| US-10280153-B2 | Process for the preparation of pure nilotinib and its salt | ABL1, ABL2, LCK | ABL1 1/4885BCR 87/4885KIT 178/4885 |
| US-20100016590-A1 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF | ABL1, FLT3, ABL2 | ABL1 1/4885BCR 5/4885KIT 515/4885 |
| US-10138221-B2 | Salts of nilotinib and polymorphs thereof | ABL1, PTPN13, PTPN1 | ABL1 1/4885BCR 28/4885KIT 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.